Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

NCT03950609 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Advanced Carcinoid Tumor
Digestive System Neuroendocrine Neoplasm
Multiple Endocrine Neoplasia Type 1
Neuroendocrine Neoplasm
Unresectable Carcinoid Tumor

Interventions

DRUG: Everolimus
DRUG: Lenvatinib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]